雌激素受体β（ERβ）对乳腺癌预后预测的Meta分析和文献综述

发布时间：2018-06-28 22:22

本文选题：乳腺癌 + 雌激素受体β　；参考：《浙江大学》2017年硕士论文

【摘要】：目的乳腺癌内分泌治疗及激素受体研究的深入,对雌激素受体β(ERβ)表达的预后意义存在争议。有研究表明ERβ表达提示预后良好,也有文献报道ERβ与预后不良有关。本文应用Meta分析系统评价乳腺癌ERβ表达的预后意义。方法通过 MEDLINE、EMBASE 和 Web of Science,检索了 1990 到 2017 年间发表的评估ERβ表达在乳腺癌患者中预后意义的相关文献。共有27项研究符合我们的纳入和排除标准,其中包括9673名患者用以评估总生存(OS)的风险比(HR)。结果27项应用免疫组织化学(IHC)、PCR和免疫印迹方法评估ERβ的公开发表的研究中,我们观察到总ERβ阳性患者(HR=0.70,95%CI 0.61-0.80,P=0.0007)总生存期(OS)显著延长;并且相比于ERα阳性亚组(HR=0.74,95%CI0.54-1.00),ERα阴性亚组中ERβ(HR=0.66,95%CI0.43-1.00)保护作用更强,而在TAM治疗亚组中(HR=0.80,95%CI(0.66,0.98)和非 TAM 治疗亚组中(HR=0.71,95%CI0.56-0.92),ERβ均表现为稳定的保护性因素。ERα/ERβ比值1时(HR=0.66,95%CI 0.55-0.79,P=0.002),ERα/ERβ 比值是乳腺癌预后的保护性因素。方法学上,免疫组化检测的ERβ水平和ERα/ERβ比值都是乳腺癌患者OS相关的预后因素。结论高ERβ水平和低ERα/ERβ比值都是改善乳腺癌患者OS的保护性预后因素。
[Abstract]:Objective to explore the prognostic significance of estrogen receptor 尾 (ER 尾) expression in endocrine therapy and hormone receptor in breast cancer. Some studies have shown that the expression of ER 尾 suggests a good prognosis, there are also reports that ER 尾 is associated with poor prognosis. The prognostic significance of ER 尾 expression in breast cancer was evaluated by Meta-analysis system. Methods by means of MEDLINE EMBASE and Web of Science, we searched the literature published from 1990 to 2017 to evaluate the prognostic significance of ER 尾 expression in breast cancer patients. A total of 27 studies met our inclusion and exclusion criteria, including 9673 patients to assess the overall survival (OS) risk ratio (HR). Results in 27 published studies using immunohistochemistry (IHC) PCR and Western blotting to evaluate ER 尾, we observed that the total survival (OS) was significantly prolonged in patients with total ER 尾 positive (CI 0.61-0.80 P0.0007). Moreover, ER 尾 was more protective in ER 伪 negative subgroup than that in ER 伪 positive subgroup (HRN 0.74 ~ 95CI0.54-1.00), whereas in TAM subgroup (HR0.80 ~ 95CI (0.660.98) and non-TAM subgroup (HRT 0.719 5CI0.56-0.92) ER 尾 was a protective factor for breast cancer. The ratio of ER 尾 to ER 伪 -ER 尾 1 (HRT 0.695 CI 0.55-0.79PU 0.002) was a protective factor for breast cancer. The ratio of ER 尾 to ER 尾 was the protective factor of breast cancer prognosis in the TAM subgroup (HR-0.80m95CI 0.6695 CI 0.55-0.79PU 0.002) and in the non-TAM subgroup (HR-0.7195CI0.56-0.92). In terms of methodology, ER 尾 levels and ER 伪 / ER 尾 ratios measured by immunohistochemistry were both prognostic factors associated with OS in breast cancer patients. Conclusion both high ER 尾 level and low ER 伪 / ER 尾 ratio are protective prognostic factors for improving OS in breast cancer patients.
【学位授予单位】：浙江大学
【学位级别】：硕士
【学位授予年份】：2017
【分类号】：R737.9

【相似文献】